I am a Project leader at our CVRM (Cardiovascular, Renal and Metabolic Diseases) IMED biotech unit. My main responsibilities are to lead the team who currently collaborate with biopharma company IONIS to create a new target to LOID, a project with the potential to impact on several features of type 2 diabetes. I am also Global Products Manager for one prominent program within type 2 diabetes, as well as for a pharmaceutical treating high cholesterol and preventing cardiovascular disease.


I started my academic career at Gothenburg University, where I later gained my PhD in 2003. I did my post-doc research at Cancer Research UK, and joined AstraZeneca Gärtuna in 2006 at the Safety Assessment department. I continued my career at AstraZeneca Södertälje in Medical Communications, before moving to Gothenburg to start as Clinical Project Manager. There, I later became Associate Director in Clinical Operations, and I have been Global Product Manager for late stage development of two treatments within cardiovascular disease for three years to date.


Being part of the IMED Biotech unit and a world class late stage project management organization at AstraZeneca is an opportunity for me to grow both as a scientist and as project leader. Collaborating with partners, such as IONIS, offers new approaches to treatments in well-known therapy areas. Creating paradigm shifts in the treatments of Cardiovascular, Renal and Metabolic Diseases really challenge us as professionals, and has great benefit for the medical society and patients alike. That´s why I am part of it all.

Per Lindblom Global Products Manager, GMD - Cardiovascular, Renal and Metabolic Diseases Project Lead, IMED Biotech unit - Cardiovascular, Renal and Metabolic Diseases

In 2012, I received the Six Sigma Green Belt Certificate, focusing on project leadership and process development. In addition, I gained the Project Management Professional Certificate in 2015. Today, I work in both early development and late stage with cardiovascular products. Recently, I joined AstraZeneca’s Optimizing Drug Development team, and led work streams to improve drug submission speed and quality process and Late stage Operating Model rollout.